November 7, 2018
Record-Setting Pace for New Drug Approvals in 2018
by Patricia Van Arnum, DCAT Editorial Director
The industry is on a record-setting pace for approvals of new molecular entities (NMEs) in 2018. As of early November, the FDA had approved 48 NMEs, outpacing 2017’s recent high of 46 approvals and nearing a high mark of 53 approvals set in 1996. Which companies made the cut, and what is the mix of small molecules and biologics? 

The EU and APIs: New Rules of the Game in Manufacturing
by Patricia Van Arnum, DCAT Editorial Director

Innovator and generic-drug companies are squaring off on a proposal by the European Commission for an export manufacturing waiver for supplementary protection certificates in the European Union. What are the implications for pharmaceutical companies and manufacturers of active pharmaceutical ingredients (APIs)?

Don't Miss Top Industry News online and in your inbox every Friday
About the Editor
Patricia Van Arnum is Editorial Director at the Drug, Chemical & Associated Technologies Association (DCAT), where she is responsible for delivering informational services for DCAT members. She is editor of two weekly editorial newsletters, DCAT Value Chain Insights and Top Industry News . She also supports DCAT’s volunteer committees and task forces that develop educational programs and informational content for DCAT members. Read More
DCAT Value Chain Insights is produced and distributed by the Drug, Chemical and Associated Technologies Association .
To learn more, please visit www.dcat.org .